Drawing for EFFIX

USPTO serial 79443342

EFFIX

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
HARDY LUDLOW, TARAH KIM
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 686 means your mark is published in the USPTO Official Gazette and in the 30-day opposition period. If no opposition is filed, prosecution typically continues toward registration or a Notice of Allowance. Monitor the opposition window. After it closes, watch for Notice of Allowance (intent-to-use) or registration (use-based).

Status 686: Status 686 means your mark is published in the USPTO Official Gazette and in the 30-day opposition period. If no opposition is filed, prosecution typically continues toward registration or a Notice of Allowance.

Need help with EFFIX?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Eric Lamb

Eric Lamb FBT Gibbons LLP111 Monument Circle, Suite 4500Indianapolis, IN 46204United States

Goods and services

ClassDescriptionStatusFirst use
001Biological preparations, other than for medical or veterinary purposes, for use in industry and science in connection with genetically modified cells and vectors for production of human, animal and synthetic proteins, for clinical and commercial purposes in scientific research and for use in pharmaceutical research; preparations of microorganisms, other than for medical and veterinary use; bacterial preparations, other than for medical and veterinary use; bacteriological preparations, other than for medical and veterinary use for use in industry and science in connection with genetically modified cells and vectors for production of human, animal and synthetic proteins, for clinical and commercial purposes in scientific research and for use in pharmaceutical research; biochemical reagents for scientific use; biochemical reagents, other than for medical use; collagen for industrial purposes; proteins for use in manufacture; protein for use in manufacture, namely, recombinant proteins expressed via microbial systems; proteins for industrial purposes; chemical additives for use in the manufacture of cosmetics; proteins for the food industry; proteins for use in the manufacture of cosmetics.ACTIVE—
005Biological preparations for medical purposes for the prevention and treatment of cancer, autoimmune diseases, infectious diseases, metabolic diseases, hereditary disorders, skin aging and aesthetic dermatological conditions; preparations of microorganisms for medical use; pharmaceutical preparations for use in the prevention and treatment of cancer, autoimmune diseases, infectious diseases, metabolic diseases, hereditary disorders, skin aging and aesthetic dermatological conditions; medicines for human purposes for use in the prevention and treatment of cancer, autoimmune diseases, infectious diseases, metabolic diseases, hereditary disorders, skin aging and aesthetic dermatological conditions; cells for medical use; bacterial preparations for medical use; all the above-mentioned goods not intended to be used in the veterinary field.ACTIVE—
040Custom manufacture of nanobodies, enzymes, cytokine, antibody fragments, virus-like particles, pDNA, antigens peptides, recombinant proteins, and vectors for others; processing and treatment of chemical reagents, namely, custom synthesis and manufacture of reagents for scientific or medical research use in the field of drug conjugation; custom manufacturing of cosmetics; custom manufacturing of pharmaceuticals; custom manufacture of biological preparations; custom manufacturing of biomedical preparations; custom manufacturing of biotechnology drugs; custom manufacturing of antibody drugs; custom manufacturing of biopharmaceuticalsACTIVE—
042Consulting services in the field of technology development in the field of protein-related biological research; research and development of new products for others; scientific research and development; biochemical research and analysis; pharmaceutical products development services; pharmaceutical research services; research in the field of synthetic biology; development of pharmaceutical preparations and medicines; biomedical research services; scientific research and development services in the field of gene expression systems.ACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 6, 2026NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Oct 6, 2026PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Sep 30, 2026NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Sep 10, 2026CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Sep 10, 2026GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Sep 10, 2026XAECEXAMINER'S AMENDMENT ENTERED—
Sep 10, 2026GNEAEXAMINERS AMENDMENT E-MAILED—
Sep 10, 2026CNEAEXAMINERS AMENDMENT -WRITTEN—
Sep 8, 2026TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Sep 8, 2026CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Sep 8, 2026TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 8, 2026ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 8, 2026REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Sep 8, 2026CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Sep 8, 2026COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Apr 9, 2026RFNTREFUSAL PROCESSED BY IB—
Mar 20, 2026RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Mar 20, 2026RFRRREFUSAL PROCESSED BY MPU—
Feb 17, 2026RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Feb 16, 2026CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 16, 2026DOCKASSIGNED TO EXAMINER—
Feb 15, 2026MAFRAPPLICATION FILING RECEIPT MAILED—
Feb 15, 2026NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Feb 12, 2026REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance